Disruptive Pharma

What Disruptive Pharma does

Disruptive Pharma is a Swedish pharmaceutical technology company headquartered in Uppsala Science Park that develops and commercializes its proprietary Formulite® platform for oral bioavailability enhancement and advanced drug formulation. The platform is based on nanostructured amorphous mesoporous magnesium carbonate (MMC), a biodegradable, polymer-free material discovered at Uppsala University (first patent filed 2012), in which APIs are stabilized in an amorphous state within a 4-8 nm pore matrix to achieve 20-50% drug loading with high dissolution and absorption. The technology has been evaluated across more than 100 APIs, with over 20 compounds progressed to pharmacokinetic studies, and a Phase 1 clinical study using sorafenib as a model compound was completed in 2025, confirming safety and functionality in humans.

The company operates a B2B enterprise partnering model targeting pharmaceutical companies, biotech companies developing NCEs, and contract development and manufacturing organizations (CDMOs). Revenue is generated through project-based partnering and development agreements (feasibility through scale-up and lifecycle management), platform commercialization via CDMO licensing, and a newer Technology Solutions business area offering MMC-based formulation services to external partners. The company also maintains internal product candidates — DPH001 (improved sorafenib for HCC/RCC) and DPH008 (prostate cancer) — to generate platform validation data and create potential out-licensing or co-development opportunities. Pricing is quote-based and not publicly disclosed.

The company was incorporated in 2021 as a spin-out from Uppsala University, is publicly listed on Nasdaq Stockholm as Disruptive Pharma Holding AB (publ), and has raised approximately 78 million SEK across three rights issues (2022, 2024, 2025). In June 2026, Guard Therapeutics announced a conditional reverse takeover agreement pending shareholder approval on July 20, 2026.

Name

Disruptive Pharma

Legal name

Disruptive Pharma AB

Website

https://disruptivepharma.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Disruptive Pharma is a Swedish pharmaceutical technology company that develops and licenses its proprietary Formulite® platform — a mesoporous magnesium carbonate (MMC) amorphization technology — to enhance oral bioavailability of poorly soluble drugs for pharma, biotech, and CDMO partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical drug formulation and bioavailability technology

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI)

Keywords

• Oral bioavailability enhancement
• Drug formulation services
• Amorphous stabilization technology
• Pharmaceutical partnering platforms
• Contract development manufacturing

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Partnering and Development Agreements: Formulation and product development projects for external partners, ranging from early feasibility assessments to advanced formulation development, product optimization, scale-up and support for lifecycle management programs. B2B tailored projects with clear technical scope, timelines, and decision points.
2. Platform Commercialization: Strategic collaborations with CDMOs and other industrial partners to enable broader industrial use of Formulite. Establishes capacity for scale-up and commercial manufacturing, creating conditions for future licensing and partnership opportunities.
3. Internal Product Candidates: Development of proprietary product candidates (DPH001 for sorafenib improvement, DPH008 for prostate cancer) to generate data and demonstrate applicability of Formulite platform, with potential for out-licensing or co-development.
4. Technology Solutions Services: Development assignments and formulation services offered within the Technology Solutions business area, providing MMC as a platform to other pharmaceutical companies developing new, improved, or differentiated products.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Disruptive Pharma develops and commercializes the proprietary Formulite® platform, a mesoporous magnesium carbonate (MMC)-based amorphization technology that enhances oral bioavailability of poorly soluble drug substances for pharmaceutical and biotech partners. The company provides tailored formulation and product development services, licenses the Formulite technology to CDMOs and industrial partners, and develops internal product candidates (DPH001, DPH008) to demonstrate and exploit the platform.

Product overview

Disruptive Pharma operates as a pharmaceutical technology company with a unified product architecture centered on its proprietary Formulite® platform. Formulite® is a next-generation amorphization technology based on biodegradable mesoporous magnesium carbonate (MMC) that enhances bioavailability of poorly soluble oral drugs. The portfolio consists of the Formulite® core technology platform, supplemented by internal product candidates (DPH001 for HCC/RCC and DPH008 for prostate cancer) that demonstrate the platform's applicability, and a Technology Solutions business area that provides formulation services and licensing to external pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• Formulite®: Proprietary bioavailability enhancement and advanced drug formulation platform based on mesoporous magnesium carbonate (MMC) technology for stabilizing drug molecules in an amorphous state to enhance solubility and bioavailability.

Products and services

• Formulite® Platform A proprietary bioavailability enhancement and advanced drug formulation platform based on mesoporous magnesium carbonate (MMC) that stabilizes APIs in an amorphous state to enhance solubility and bioavailability for poorly soluble oral drugs, offered to pharmaceutical and biotech partners via licensing and platform commercialization.
• DPH001 Internal product candidate using the Formulite® MMC platform to deliver an improved sorafenib formulation targeting hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), demonstrating bioequivalent exposure at 50% API dose versus NEXAVAR® and reduced inter-animal variability in preclinical studies.
• DPH008 Internal product candidate for prostate cancer developed on the Formulite® MMC technology platform, intended to generate data demonstrating platform applicability and create out-licensing or co-development opportunities.
• Technology Solutions Business area offering the Formulite®/MMC platform as a service to other pharmaceutical companies, providing formulation development projects, feasibility assessments, advanced formulation development, product optimization, scale-up support, and lifecycle management through partnering and development agreements.

Quantifiable outcome

• Bioequivalent exposure achieved at 50% API dose compared to standard formulation (sorafenib/NEXAVAR)
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• CytoCrox: Swedish drug-delivery company developing inhaled and reformulation technologies using novel carrier systems. Comparable Scandinavian base and focus on reformulating approved molecules via differentiated delivery platforms — partial overlap with Disruptive Pharma's supergeneric positioning.
• Ascendia Pharmaceuticals: New Jersey-based specialty CDMO focused on poorly soluble drugs via nanoemulsions, amorphous dispersions, and lipid-based formulations. Closely mirrors Disruptive Pharma's positioning as a formulation technology specialist serving similar pharma/biotech customers.
• Nanologica: Swedish nanoporous silica drug delivery company developing bioavailability solutions — notably staffed by former Disruptive Pharma Director R&D Malin Vågerö. Comparable Swedish base, nanoporous-carrier approach for poorly soluble APIs, and similar early-commercial stage.
• iCeutica: Australia/US specialty company developing amorphous drug formulations via the SoluMatrix fine-particle platform. Direct comparable in applying novel amorphization approaches to poorly soluble APIs, including reformulation plays like Disruptive Pharma's DPH001/DPH008.

Broad incumbents

• Recipharm: Swedish-headquartered global CDMO offering formulation development and commercial manufacturing — listed by Disruptive Pharma's Commercial Director Martina Ferneman among her prior employers. Overlapping customer base and Sweden-based operating footprint.
• Catalent: Global CDMO incumbent offering OptiMelt hot-melt extrusion and spray-dried dispersion (SDD) platforms for bioavailability enhancement. Directly competes with Formulite in the oral-formulation partnership market, serving the same Big Pharma and biotech customers.
• Lonza Capsules & Health Ingredients: Lonza's Capsugel business includes bioavailability and amorphous formulation services (formerly Bend Research). Competes with Formulite in offering pharma partners differentiated oral bioavailability solutions with global manufacturing footprint.

Direct peers

• Ardena: European CDMO offering formulation development, analytical services, and GMP manufacturing for poorly soluble drugs. Directly comparable to Disruptive Pharma's Technology Solutions business area and overlapping European pharma/biotech customer base.
• Quotient Sciences: UK/US CDMO focused on integrated formulation development, real-time adaptive manufacturing, and bioavailability enhancement for pharma partners. Comparable service offering (formulation-to-clinic) and overlapping customer base make it a close operational peer.
• Hovione: Portugal-based CDMO with deep expertise in amorphous solid dispersions, particle engineering, and bioavailability enhancement. Highly comparable to Disruptive Pharma as both serve pharma partners seeking solubility/bioavailability solutions, though Hovione operates at much larger scale with spray drying and other established platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/disruptive-pharma-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Disruptive Pharma